News

The US Food and Drug Administration (FDA) has cleared Cumberland’s investigational new drug application (IND) for Phase II clinical program for Vasculan in patients with systemic sclerosis. "Cumberland

X-Chem met this milestone under a partnership established with Alexion in December 2014. Under the terms of the agreement, Alexion obtains exclusive worldwide rights to develop and commercialize

IBC Generium chief business officer Daniil Talyanskiy said: "Our scientific staff at IBC Generium developed GNR-047, an IgG-based anti-CD3 / anti-CD19 bispecific antibody for the treatment of oncohematological

Based on this review, the company intends to initiate the first of two Phase 3 clinical trials during the third quarter of 2016. The FDA has stated that

The open-label study will assess the safety and tolerability of the drug in patients with unresectable stage IIIB or IV, gpNMB-expressing, advanced or metastatic squamous cell carcinoma (SCC)

The three conditions for which Ilaris is being reviewed include tumor necrosis factor-receptor associated periodic syndrome (TRAPS) and Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), and Familial Mediterranean

Under the agreement, GSK will have the option to develop and commercialize multiple bi-specific drugs across different disease areas. Zymeworks will receive upfront and preclinical payments of up

The orphan medicinal products designation is recommended for the two active ingredients of AB569, sodium nitrite and ethylenediaminetetraacetic acid (EDTA). The positive opinion will now be forwarded to

Xtampza ER is an opioid agonist product indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options